Part of Amgen's tax savings to go into $300M U.S. biologics plant, 300 new jobs

Part of Amgen's tax savings to go into $300M U.S. biologics plant, 300 new jobs

Amgen, which in 2014 opened this modular, more-efficient biologics manufacturing facility in Singapore, will now build a similar operation somewhere in the U.S. (Amgen)

Amgen designed a biologics manufacturing plant several years ago that was smaller, cheaper and more flexible than the traditional giant-sized, drug-specific model. Then it built it in low-cost Singapore. Now, motivated by U.S. tax breaks, Amgen will invest up to $300 million to build a plant in the U.S. and hire hundreds of workers.